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OBJECTIVES: To explore the association of global treat-
ment response with improvement in negative symptoms
and quality of life (QoL). 
METHODS: Data was analyzed from a large, prospec-
tive, randomized, 28-week, double-blind trial of olanza-
pine (OLZ) vs. risperidone (RIS) in schizophrenic patients
(N = 339). Global treatment response was classiﬁed 
by categorical improvement on Positive and Negative 
Syndrome Scale (PANSS) total score at 28-week: <20%;
20–40%; and ≥40% improvement. The proportion 
of responders for Scale for Assessment of Negative 
Symptoms (SANS) and Quality of Life Scale (QLS) scores
were compared across groups. 
RESULTS: There was a signiﬁcant positive association
between level of global treatment response and improve-
ments in negative symptoms and QLS. Only patients 
with 20% or greater improvement in PANSS accessed
improvement in SANS and QLS. In the highest PANSS
response group, the proportion of patients with ≥40%
improvement in QLS was 60.9% for OLZ versus 32.1%
for RIS (p = 0.02). Similar observations were demon-
strated in improvement on the SANS. 
CONCLUSIONS: A more robust categorical global treat-
ment response was associated with greater improvement
in negative symptoms and QoL. Olanzapine treatment
may provide more patients access to the requisite high
threshold of global response.
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OBJECTIVES: Recent studies have shown that initiating
treatment for major depressive disorders with venlafax-
ine may lead to lower subsequent treatment costs than the
SSRIs and that three of the major SSRIs are similar to one
another. Our objective is to provide updated evidence by
comparing a year of depression-related costs for patients
initiating therapy on any of three SSRIS with each other
and with venlafaxine. 
METHODS: Patients with a depression diagnosis and a
prescription for ﬂuoxetine, paroxetine, sertraline, or 
venlafaxine between October 1997 and September 1998
were selected from Protocare Sciences’ managed care
claims database. After excluding patients who had 
antidepressant prescriptions within 6 months prior to
their index prescription and patients with any antipsy-
chotic prescriptions, 8800 remained for study. Logit
propensity score models were constructed of the therapy
initiation choices. The patients were stratiﬁed according
to propensity score quintiles to reduce the potential
therapy-selection bias. Within each stratum, the total
claims costs, depression-related costs, and antidepressant
prescription costs during the year following the patient’s
index antidepressant were computed and compared in
terms of mean differences and geometric mean ratios 
of pairs of antidepressants. Precision-weighted ratios,
conﬁdence intervals, and overall signiﬁcance levels were
summed across all ﬁve strata. 
RESULTS: The precision-weighted geometric mean ratios
of depression-related costs indicate that venlafaxine is
higher than the SSRIs although with marginal signiﬁcance
(1.12, CI: 0.99–1.28), ﬂuoxetine is higher than either
paroxetine (1.33, CI: 1.23–1.43) or sertraline (1.31, CI:
1.22–1.40) and there is no signiﬁcant difference between
paroxetine and sertraline (0.99, CI: 0.93–1.05). However,
the total costs of health care claims are not signiﬁcantly
different among the four study drugs. The mean (and
median) depression-related costs are venlafaxine $1,324
($540), ﬂuoxetine $1,139 ($558), paroxetine $1,022
($391), and sertraline $925 ($425). 
CONCLUSIONS: In this managed care setting there is a
difference in depression-related treatment costs between
venlafaxine and the SSRIs and between ﬂuoxetine and the
other SSRIs, although the magnitude of the difference is
not large.
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Depressive disorders are a common reason for visits 
to primary care physicians (PCPs). While clinical trials
demonstrate the efﬁcacy of pharmacotherapies, response
rates for patients in PCP settings are low. 
OBJECTIVE: The objective of this study was to look at
clinical response taking into account treatment patterns,
and to compare outcomes for remitters, non-responders,
and partial responders to better understand factors
related to response in PCP settings. 
METHODS: A prospective, Randomized Trial Investi-
gating SSRI Treatment (ARTIST) compared effectiveness
